Is Presixion a funded company?

Presixion is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Presixion rank among its competitors?

Presixion ranks 62nd amongst 62 active competitors, of which 15 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Alveo Technologies, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Presixion?

Presixion's top competitors include Molbio Diagnostics, Alveo Technologies and Lumos Diagnostics. Among them, Alveo Technologies secured the most recent funding round in May, 2026.

Presixion - 2026 Company Profile & Competitors

Presixion is an unfunded company. It operates as a Manufacturer of multi-channel lateral flow assay tests for infectious diseases. Presixion has not raised any funding yet. The company has 62 active competitors, including 15 funded and 5 that have exited. Its top competitors include companies like Molbio Diagnostics, Alveo Technologies and Lumos Diagnostics.

Company Details

Manufacturer of multi-channel lateral flow assay tests for infectious diseases. These diagnostic tools screen for respiratory illnesses to facilitate medical care and reduce the transmission of infections. The products are designed for individual use to support health monitoring.

Key Metrics

Stage

Unfunded

Ranked

62^nd among 62 active competitors

Similar Companies

Molbio Diagnostics & 60 more

View Presixion's full profile

Presixion has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Presixion include Molbio Diagnostics, Alveo Technologies and Lumos Diagnostics. Here is the list of Top 10 competitors of Presixion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Molbio Diagnostics 2000, Salcete (India), Series C	Developer of point-of-care molecular diagnostic platform for infectious disease detection	$124M	Motilal Oswal, Temasek & 36 others	71/100
2nd	Alveo Technologies 2015, Alameda (United States), Series A	Developer of a portable molecular diagnostics platform	$63.6M	4-Good Ventures, Celesta Capital & 8 others	61/100
3rd	Lumos Diagnostics 2017, Carlsbad (United States), Public	Provider of rapid point-of-care diagnostic test solutions	$40M	Perennial, Ellerston Capital & 2 others	58/100
4th	SD Biosensor 2001, Suwon-si (South Korea), Public	Provider of point-of-care diagnostics for multiple diseases	-	Gates, InterVest & 3 others	55/100
5th	Proxim Diagnostics 2010, Sunnyvale (United States), Series B	Developer of a handheld immunodiagnostic device for cardiac vascular diseases	$22.9M	BioMerieux, UCLA Ventures & 1 others	52/100
6th	QuantuMDx Group 2008, Newcastle Upon Tyne (United Kingdom), Series D	Manufacturer of molecular diagnostic platforms and assays for infectious diseases	$57.3M	Adjuvo, WG Partners & 3 others	49/100
7th	MedMira 1993, Halifax (Canada), Public	Diagnostic devices for rapid multiplex immuno-testing	$6.5M	Morningside, Jai Capital & 1 others	49/100
8th	Access Bio 2001, Somerset (United States), Public	Global in-vitro diagnostics company dedicated to preventing and diagnosing infectious diseases	$12M	STIC Investments, Global Health Investment Fund ... & 4 others	48/100
9th	ShanX Medtech 2019, Eindhoven (Netherlands), Seed	Provider of in vitro diagnostic platforms for antibiotic testing	$17.5M	Borski Fund, Invest-NL & 4 others	47/100
10th	Kryptos Biotechnologies 2017, Hayward (United States), Series A	Biotechnology company illuminating complex diseases with innovative diagnostic and life science solutions	$12.7M	FuturePlay, KBD Capital & 6 others	45/100
62nd	Presixion Unfunded	Manufacturer of multi-channel lateral flow assay tests for infectious diseases	-	-	-